158 related articles for article (PubMed ID: 21749132)
1. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue.
Yasunaga M; Manabe S; Tarin D; Matsumura Y
Bioconjug Chem; 2011 Sep; 22(9):1776-83. PubMed ID: 21749132
[TBL] [Abstract][Full Text] [Related]
2. Tailored immunoconjugate therapy depending on a quantity of tumor stroma.
Yasunaga M; Manabe S; Tarin D; Matsumura Y
Cancer Sci; 2013 Feb; 104(2):231-7. PubMed ID: 23121194
[TBL] [Abstract][Full Text] [Related]
3. Cancer stromal targeting (CAST) therapy.
Matsumura Y
Adv Drug Deliv Rev; 2012 Jun; 64(8):710-9. PubMed ID: 22212902
[TBL] [Abstract][Full Text] [Related]
4. New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots.
Yasunaga M; Manabe S; Matsumura Y
Cancer Sci; 2011 Jul; 102(7):1396-402. PubMed ID: 21481097
[TBL] [Abstract][Full Text] [Related]
5. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab Deruxtecan: First Approval.
Keam SJ
Drugs; 2020 Apr; 80(5):501-508. PubMed ID: 32144719
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.
Burke PJ; Senter PD; Meyer DW; Miyamoto JB; Anderson M; Toki BE; Manikumar G; Wani MC; Kroll DJ; Jeffrey SC
Bioconjug Chem; 2009 Jun; 20(6):1242-50. PubMed ID: 19469529
[TBL] [Abstract][Full Text] [Related]
8. Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor.
Hu B; Du HJ; Yan GP; Zhuo RX; Wu Y; Fan CL
Drug Deliv; 2014 May; 21(3):204-12. PubMed ID: 24117028
[TBL] [Abstract][Full Text] [Related]
9. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Purcell JW; Tanlimco SG; Hickson J; Fox M; Sho M; Durkin L; Uziel T; Powers R; Foster K; McGonigal T; Kumar S; Samayoa J; Zhang D; Palma JP; Mishra S; Hollenbaugh D; Gish K; Morgan-Lappe SE; Hsi ED; Chao DT
Cancer Res; 2018 Jul; 78(14):4059-4072. PubMed ID: 29764866
[TBL] [Abstract][Full Text] [Related]
10. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.
Kurtzberg LS; Roth S; Krumbholz R; Crawford J; Bormann C; Dunham S; Yao M; Rouleau C; Bagley RG; Yu XJ; Wang F; Schmid SM; Lavoie EJ; Teicher BA
Clin Cancer Res; 2011 May; 17(9):2777-87. PubMed ID: 21415217
[TBL] [Abstract][Full Text] [Related]
11. Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).
Pandey R; Gruslova A; Chiou J; Brenner AJ; Tiziani S
Anal Chem; 2020 Jan; 92(1):1260-1267. PubMed ID: 31765123
[TBL] [Abstract][Full Text] [Related]
12. A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors.
Miao Z; Zhu L; Dong G; Zhuang C; Wu Y; Wang S; Guo Z; Liu Y; Wu S; Zhu S; Fang K; Yao J; Li J; Sheng C; Zhang W
J Med Chem; 2013 Oct; 56(20):7902-10. PubMed ID: 24069881
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly(ethylene glycol) and dipeptide for the development of immunoconjugate.
Suzawa T; Nagamura S; Saito H; Ohta S; Hanai N; Yamasaki M
J Control Release; 2000 Oct; 69(1):27-41. PubMed ID: 11018544
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific novel taxoid-monoclonal antibody conjugates.
Ojima I; Geng X; Wu X; Qu C; Borella CP; Xie H; Wilhelm SD; Leece BA; Bartle LM; Goldmacher VS; Chari RV
J Med Chem; 2002 Dec; 45(26):5620-3. PubMed ID: 12477344
[TBL] [Abstract][Full Text] [Related]
15. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
Mazor Y; Noy R; Wels WS; Benhar I
Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma.
Sun F; Wang Y; Luo X; Ma Z; Xu Y; Zhang X; Lv T; Zhang Y; Wang M; Huang Z; Zhang J
Cancer Res; 2019 Jul; 79(13):3395-3405. PubMed ID: 30918001
[TBL] [Abstract][Full Text] [Related]
17. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
18. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.
Szot C; Saha S; Zhang XM; Zhu Z; Hilton MB; Morris K; Seaman S; Dunleavey JM; Hsu KS; Yu GJ; Morris H; Swing DA; Haines DC; Wang Y; Hwang J; Feng Y; Welsch D; DeCrescenzo G; Chaudhary A; Zudaire E; Dimitrov DS; St Croix B
J Clin Invest; 2018 Jul; 128(7):2927-2943. PubMed ID: 29863500
[TBL] [Abstract][Full Text] [Related]
19. Simply mixing with poly(ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin family.
Ci T; Li T; Chang G; Yu L; Ding J
J Control Release; 2013 Aug; 169(3):329-35. PubMed ID: 23246468
[TBL] [Abstract][Full Text] [Related]
20. Naptumomab estafenatox: a new immunoconjugate.
Robinson MK; Alpaugh RK; Borghaei H
Expert Opin Biol Ther; 2010 Feb; 10(2):273-9. PubMed ID: 20053143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
